TITLE

High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models

AUTHOR(S)
Yost, Shawn E.; Pastorino, Sandra; Rozenzhak, Sophie; Smith, Erin N.; Chao, Ying S.; Jiang, Pengfei; Kesari, Santosh; Frazer, Kelly A.; Harismendy, Olivier
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recent advances in the ability to efficiently characterize tumor genomes is enabling targeted drug development, which requires rigorous biomarker-based patient selection to increase effectiveness. Consequently, representative DNA biomarkers become equally important in pre-clinical studies. However, it is still unclear how well these markers are maintained between the primary tumor and the patient-derived tumor models. Here, we report the comprehensive identification of somatic coding mutations and copy number aberrations in four glioblastoma (GBM) primary tumors and their matched pre-clinical models: serum-free neurospheres, adherent cell cultures, and mouse xenografts. We developed innovative methods to improve the data quality and allow a strict comparison of matched tumor samples. Our analysis identifies known GBM mutations altering PTEN and TP53 genes, and new actionable mutations such as the loss of PIK3R1, and reveals clear patient-to-patient differences. In contrast, for each patient, we do not observe any significant remodeling of the mutational profile between primary to model tumors and the few discrepancies can be attributed to stochastic errors or differences in sample purity. Similarly, we observe ∼96% primary-to-model concordance in copy number calls in the high-cellularity samples. In contrast to previous reports based on gene expression profiles, we do not observe significant differences at the DNA level between in vitro compared to in vivo models. This study suggests, at a remarkable resolution, the genome-wide conservation of a patient’s tumor genetics in various pre-clinical models, and therefore supports their use for the development and testing of personalized targeted therapies.
ACCESSION #
87624365

 

Related Articles

  • The PIK3CA Gene as a Mutated Target for Cancer Therapy. Gustin, John P.; Cosgrove, David P.; Park, Ben Ho // Current Cancer Drug Targets;Dec2008, Vol. 8 Issue 8, p733 

    The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can...

  • Biomarker Selection: Be an: Early Bird? Or a Late Arriver? Breindl, Anette // BioWorld Insight;6/11/2012, Vol. 20 Issue 24, p3 

    The article focuses on biomarkers for the detection of mutation and development of drugs. It mentions the co-development of a targeted therapeutic with a companion diagnostic. It also discusses the time to start with the development of targeted drugs. It also raises the concern over the use of...

  • Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. Zhang, Guo-Bin; Cui, Xiang-Li; Sui, Da-Li; Ren, Xiao-Hui; Zhang, Zhe; Wang, Zhong-Cheng; Lin, Song // Journal of Neuro-Oncology;Jul2013, Vol. 113 Issue 2, p251 

    This study was designed to find whether long-term survivors (LTSs) exhibit molecular genetic differences compared with short-term survivors (STSs) in patients with GBM. Tumors from 12 patients initially diagnosed with GBM and survived longer than 36 months (LTSs) were compared with 30 patients...

  • IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. Amelot, Aymeric; De Cremoux, Patricia; Quillien, Véronique; Polivka, Marc; Adle-Biassette, Homa; Lehmann-Che, Jacqueline; Françoise, Laurence; Carpentier, Antoine F.; George, Bernard; Mandonnet, Emmanuel; Froelich, Sébastien // PLoS ONE;7/9/2015, Vol. 10 Issue 7, p1 

    Background: A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a small subgroup of GBM patients with favourable prognosis. However, it remains controversial whether long-term survivors (LTS)...

  • AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models. Chang, Edwin; Pohling, Christoph; Natarajan, Arutselvan; Witney, Timothy; Kaur, Jasdeep; Xu, Lingyun; Gowrishankar, Gayatri; D'Souza, Aloma; Murty, Surya; Schick, Sophie; Chen, Liyin; Wu, Nicholas; Khaw, Phoo; Mischel, Paul; Abbasi, Taher; Usmani, Shahabuddin; Mallick, Parag; Gambhir, Sanjiv // Journal of Neuro-Oncology;Jan2016, Vol. 126 Issue 2, p253 

    Glioblastoma multiforme (GBM) is an aggressive, malignant cancer Johnson and O'Neill (J Neurooncol 107: 359-364, ). An extract from the winter cherry plant ( Withania somnifera ), AshwaMAX, is concentrated (4.3 %) for Withaferin A; a steroidal lactone that inhibits cancer cells Vanden Berghe et...

  • A 16-Gene Signature Distinguishes Anaplastic Astrocytoma from Glioblastoma. Rao, Soumya Alige Mahabala; Srinivasan, Sujaya; Patric, Irene Rosita Pia; Hegde, Alangar Sathyaranjandas; Chandramouli, Bangalore Ashwathnarayanara; Arimappamagan, Arivazhagan; Santosh, Vani; Kondaiah, Paturu; Rao, Manchanahalli R. Sathyanarayana; Somasundaram, Kumaravel // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Anaplastic astrocytoma (AA; Grade III) and glioblastoma (GBM; Grade IV) are diffusely infiltrating tumors and are called malignant astrocytomas. The treatment regimen and prognosis are distinctly different between anaplastic astrocytoma and glioblastoma patients. Although histopathology based...

  • The effect of a single BRCA2 mutation on cancer in Iceland. Tulinius, H.; Olafsdottir, G.H.; Sigvaldason, H.; Arason, A.; Barkardottir, R.B.; Egilsson, V.; Ogmundsdottir, H.M.; Tryggvadottir, L.; Gudlaugsdottir, S.; Eyfjord, J.E. // Journal of Medical Genetics;Jul2002, Vol. 39 Issue 7, p457 

    Objective: To estimate the risk of malignant diseases in families of probands with the same mutation in the BRCA2 gene. Design: A cohort study using record linkage of a breast cancer family resource and the Icelandic Cancer Registry. Setting: Iceland. Subjects: Families of 995 breast cancer...

  • Cancer genetics: Finding the right mix. Boehm, Jesse S.; Hahn, William C. // European Journal of Human Genetics;Oct2005, Vol. 13 Issue 10, p1099 

    Reports on the development of experimental models of melanoma that may facilitate the identification of cooperating transforming mutations. Publication of the study in the 2005 issue of the periodical "Human Genetics"; Evidence supporting the notion that it may one day be possible to screen...

  • NCI commences genetic cancer marker initiative.  // Urology Times;4/1/2006, Vol. 34 Issue 4, p6 

    The article reports on the National Cancer Institute's initiation of a three-year study to identify the genetic mutations that increase the risk of prostate and breast cancer. The National Cancer Institute is part of the National Institutes of Health. The article highlights the objectives of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics